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A B S T R A C TObjectives: Venous thromboembolism (VTE) is the most frequent
complication following major orthopaedic surgery (MOS). Although
studies in Western populations have demonstrated significantly
higher costs for patients with VTE versus those without VTE after
MOS, there is a paucity of such data in Japan. This study was
conducted to understand the costs and VTE rates in Japanese patients.
Methods: Data were extracted from a hospital claims database. MOS
was defined as total hip replacement, total knee replacement, or hip
fracture repair. Subjects who underwent more than one MOS during
the same admission were excluded. Identified VTE cases were
matched on a 1:2 matching scheme on the basis of surgery type,
hospital, and date of surgery (6 months). The primary outcome was
the difference in 90-day costs. Secondary outcomes included differ-
ences in total 6-month costs postsurgery and average length and cost
of initial hospital stay. Results: The 90-day cumulative VTE incidencesee front matter Copyright & 2013, International
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ndence to: Bruce Crawford, Adelphi Values, Arco Twas 0.774%, with 94% of the cases occurring within 30 days post-
surgery. Total 90-day costs were significantly higher in patients with
VTE (difference of 864,153 Japanese yen [US $10,538]). Average length
of stay was longer for patients with VTE (66 days vs. 42 days). Costs
incurred by patients with VTE were on average much higher than
those incurred by patients without VTE throughout 5 months
postsurgery. Conclusions: The development of a VTE in patients
undergoing MOS results in a 1.5-fold increase in the length of stay
and a 1.7-fold increase in 90-day costs. Findings indicate that the
avoidance of VTEs through more effective prophylaxis will help to
reduce the economic burden associated with MOS.
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Venous thromboembolism (VTE) is the most frequent complica-
tion following major orthopaedic surgery (MOS) [1]. It can occur
as a result of persistent venous injury or impaired venous
function, prolonged immobilization, impairment of endogenous
anticoagulant or fibrinolytic systems, or clots in the pelvic region
or contralateral extremity, postoperatively [1,2]. Deep vein throm-
bosis (DVT) may be associated with sequelae including recurrent
VTE and postthrombotic syndrome. Postthrombotic syndrome
may, in turn, result in persistent symptoms of chronic edema,
discomfort, dermatitis, ambulatory venous hypertension, and
venous ulceration [1,3].
Prevalence of DVT has been found to be among the highest in
orthopaedic procedures than in other surgery types. The inci-
dence of pulmonary embolism (PE) is much less certain; however,
3% to 28% of the patients undergoing total hip replacement (THR)
and total knee replacement (TKR) were found to be at a high risk
of developing PE within 2 weeks following surgery. Moreover, VTE
is the most common cause for hospital readmission after THR [1].International consensus recommendations include routine
thromboprophylaxis in patients undergoing MOS; however, phar-
macological prophylaxis is not routinely administered in Asian
populations because VTE incidence is thought to be low. These
VTE incidence rates in Asian patients, however, have been
reported to be similar to those in Western patients. In a pro-
spective epidemiological study, the incidence of DVT in Asian
patients who did not receive any pharmacological thrombopro-
phylaxis was 58.1% after TKR and 42% after hip fracture surgery,
compared with previously reported incidence rates of 40% to 74%
and 36% to 60%, respectively, in Western patients [1]. Moreover,
the incidence rates of asymptomatic DVT following TKR, hip
fracture surgery, and THR were 43%, 24%, and 17%, respectively.
The difficulty in diagnosing VTE because of frequently clinically
silent events or unreliable clinical signs highlights the risk of PE-
related sudden death being the first clinical manifestation [4].
Approximately 10% of the deaths during hospitalization are
attributed to PE [1].
Despite the fact that PE has been identified as a major cause of
sudden death following surgery, it is not diagnosed in 22% of theSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Western patients reported fatal initial PE and fatal recurrent PE
rates of 1% and 0.3%, respectively, at 3 months after MOS [6].
However, DVT and PE following THR have been shown to increase
the mortality rates by nearly 5 times and nearly 66 times,
respectively [7]. In Japan, the number of PE cases increased from
3492 cases in 1996 to 4020 cases in 2000 and mortality rates due to
acute PE are 20% to 30% [8,9]. According to the guidelines for VTE
diagnosis, treatment, and prevention, published by the Japanese
Circulation Society in 2009, the number of PE-related deaths have
increased by approximately 1.5-fold in 2005 compared with 1995
[10]. In addition, mortality rates associated with PE are reportedly
higher (11.9%) than those of acute myocardial infarction (7.3%) [11].
Symptomatic DVT and PE have been associated with serious
and negative outcomes including considerable acute morbidity,
substantial consumption of resources, and long-term clinical
sequelae, which result in greatly increased health care costs [1].
Studies in Western populations have demonstrated significantly
higher costs for patients with VTE than for patients without the
complication after MOS. The occurrence of VTE was found to
increase total hospitalization days by greater than 2-fold and
time spent in the intensive care unit by almost 10-fold. These
result in overall costs for patients with VTE that are twice those
for patients without VTE [7]. Overall health care charges over
a period of 3 months have been reported to increase by 63%
because of postdischarge VTE following hip replacement, major
knee surgery, or hip fracture repair (P o 0.01) [12]. There is a
paucity of literature, however, that report the cost of VTE
following MOS in Japan and other Asian countries.
Health care payers and policymakers would like to have
information about the costs associated with diseases and their
treatments. These data, however, are often not available from
randomized clinical trials, which are the main source of clinical
information. Specifically, because randomized clinical trials are
often limited by atypical settings, artificial protocols, and highly
selected populations due to strict screening criteria and short
follow-up periods, their results may not reflect ‘‘real-world’’
outcomes. However, claims databases typically contain informa-
tion from demographically and geographically diverse popula-
tions that are available for longer periods of time. These allow for
better representation of the general population and real-life
settings, which are more suitable for pharmacoeconomic evalua-
tions [13]. Therefore, this study set out to analyze the costs
associated with VTE following MOS using a claims database
in Japan.Methods
Data were extracted from the Medical Data Vision, Inc., database,
a hospital claims database that contains detailed electronic
hospital medical records from 13 private or governmental hospi-
tals from Hokkaido, Tohoku, Kanto, Chubu, and Kansai prefec-
tures. Data were extracted on major orthopaedic surgeries
between January 1, 2003, and October 31, 2009.
Study Subjects
Major orthopaedic surgeries were defined as a principal proce-
dure of THR, TKR, or hip fracture repair, and were identified by
using ReceCodes, which are standardized codes used by the
Ministry of Health, Labour and Welfare for electronic claims
processing. These codes are associated to the following Interna-
tional Classification of Diseases, Ninth Revision, Clinical Modification,
codes: 79.25, 81.51, 81.52, and 81.54. Inclusion criteria were aged
18 years or older, having at least 3 months of data prior to the
index surgery, and having 3 to 6 months of postsurgery dataavailable or died within this time period. Subjects who under-
went more than one MOS during the same admission were
excluded.
VTE Cases
Warfarin and heparin are commonly used for VTE prophylaxis.
According to guidelines for the prophylaxis and treatment of VTE
that were published in Japan in 2004, standard pharmacological
treatment includes unfractionated heparin (UFH) followed by
warfarin for at least 3 months, with the presence of risk factors
that are reversible. Treatment may be administered for at least
6 months when there are no apparent risk factors associated with
VTE incidence [10]. Given that prophylactic treatment cannot be
prescribed without an associated diagnostic code, utilizing only
the administration of low molecular weight heparin or warfarin
would result in an excessively high false-positive VTE rate.
Therefore, candidate VTE cases were identified by using Rece-
Codes associated with International Classification of Diseases, Tenth
Revision, codes for PE (I269) and DVT (I801, I802, and I803),
followed by additional strict criteria to ensure that subjects were
true VTE cases. Following the identification of PE and DVT codes,
subjects were required to have a DVT or PE diagnosis code up to
90 days after their first surgery and no diagnosis from 90 to 7 days
before surgery. This allowed for the identification of a VTE up to
90 days postsurgery. Because prophylactic treatment may be
administered prior to surgery, we allowed prophylaxis to be
administered for up to 1 week prior to surgery. VTE codes
identified earlier than this may be from prior VTE and therefore
they would not be considered ‘‘at risk’’ of a VTE following surgery.
Subjects additionally need to have warfarin or UFH initiated
within 1 day of VTE diagnosis, followed by anticoagulant use for
more than 28 days after initiation. One day was selected to
account for a delay in data entry within the hospital database.
The use of UFH or warfarin for at least 28 days allowed for the
exclusion of subjects assumed on prophylaxis treatment only,
despite having a VTE diagnosis code. In addition, subjects with an
inferior vena cava filter placement (International Classification of
Diseases, Ninth Revision, Clinical Modification, code of 38.7) within
128 days of surgery were assumed to have a PE.
Matched Controls
Identified cases were matched to control subjects without VTE on
a 1:2 matching scheme on the basis of surgery type, hospital, and
date of surgery (6 months). These criteria allowed for the
reduction of impact of treatment practice changes that may
influence the costs and resource utilization associated with
surgery and VTE management.
Control subjects were included in the study if their primary
point of contact for clinical care was the hospital where they
underwent surgery, to ensure that all treatment costs associated
with the surgery and any postdischarge care were fully captured.
Therefore, subjects were required to have at least a 3- to 6-month
postsurgery visit.
Pharmacoeconomic Analyses
The primary outcome measure was the 90-day costs associated
with surgery. The secondary outcomes were total costs for 6
months following surgery, average length of hospital stay for the
initial admission, and cost of the hospital stay. Total costs
consisted of pharmacy, laboratory, medical treatment, and room
charges. Total costs between patients with VTE and patients
without VTE were evaluated by using a gamma-distributed
generalized linear model with a log-link function. The gamma-
distributed functional form is particularly useful because
it avoids the issues with retransformation of skewed data.
Table 1 – Patient demographic information for VTE
cases and matched controls with at least 90 d of
follow-up data.
Cases Matched
controls
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analyzed on the basis of 1000 draws with replacement. Untrans-
formed costs were evaluated by using t tests/analysis of variance,
and median differences were tested by using the Mann-Whitney
U/Wilcoxon rank-sum test. Costs are presented as Japanese yen
(JPY) and US dollars (82 JPY ¼ US $1).(n ¼ 26) (n ¼ 51)
Gender, n (%)
Male 2 (7.7) 6 (11.8)
Female 24 (92.3) 45 (88.2)
Age (y) at time of procedure
Mean  SD 75.4  12.23 76.5  13.65
Median 77.00 79.00
Min-Max 40.0–96.0 24.0–98.0
Age categorized (y), n (%)
o70 7 (26.9) 9 (17.6)
70–79 9 (34.6) 18 (35.3)
Z80 10 (38.5) 24 (47.1)
Surgical intervention, n (%)
Hip fracture repair 16 (61.5) 31 (60.8)
Hip replacement 5 (19.2) 10 (19.6)
Knee replacement 5 (19.2) 10 (19.6)
Note. Controls matched on MOS date, surgery type, and clinic.
MOS, major orthopaedic surgery; VTE, venous thromboembolism.Results
The pool of potential cases consisted of 4650 patients who
underwent MOS and did not have a prior diagnosis of VTE
between 8 and 90 days prior to surgery. Among these, a total of
37 patients were identified to be true cases having had their first
DVT and/or PE occurrence 0 to 7 days after surgery (12 patients), 8
to 14 days after surgery (19 patients), 15 to 30 days after surgery
(3 patients), 31 to 60 days after surgery (2 patients), or 61 to 90
days after surgery (1 patient). These results are presented in
Figure. 1. One patient had more than one VTE occurrence.
Therefore, within this cohort of MOS patients, there was a 90-
day cumulative VTE incidence of 0.774%, with 94% of the cases
occurring within the first 30 days following surgery.
Ten patients that were true cases did not have adequate data
for the 90-day follow-up period, and therefore were not included
in the demographics and cost analyses. A total of 26 cases had
data for at least a 90-day follow-up period and were matched to
51 controls. One case could be matched to only one control
instead of two. Twenty-five patients were identified as DVT cases
with 49 matched controls. Eight patients were identified as PE
cases with 15 matched controls. A total of 7 patients had both
DVT and PE.
The mean age of the 26 patients with VTE was 75.4 12.23
years, ranging from 40 to 96 years, and the mean age of the 51
matched controls was 76.5 13.65 years, ranging from 24 to 98
years. Most were female patients in both the VTE (92.3%) and
matched control (88.2%) groups, with more than half having a hip
fracture repair. Demographic information for patients with at
least 90 days of follow-up data is presented in Table 1.
The total 90-day cost associated with surgery for patients with
VTE was on average 1,992,713 JPY ($24,301) compared with an
average of 1,128,560 JPY ($13,763) for matched control patients
without VTE, resulting in a difference of 864,153 JPY ($10,538)
(bootstrapped 95% confidence interval [95% CI] 436,131.98
JPY–1,245,447.28 JPY [$5,319– $15,188]). Costs for patients with0
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Fig. 1 – Time course of VTE incidence following MOS. MOS,
major orthopaedic surgery; VTE, venous thromboembolism.VTE were significantly higher when tested with the gamma-
distributed log-link generalized linear model adjusted for age and
gender (Po 0.0001). The 90-day cost associated with surgery for
patients with DVT was on average 1,910,365 JPY ($23,297) com-
pared with 1,159,583 JPY ($14,141) for matched controls, resulting
in a difference of 750,782 JPY ($9,156) (bootstrapped 95% CI
401,624.32 JPY–1,159,133.60 JPY [$4,898–$14,136]). For patients
with PE, the 90-day cost associated with surgery was on average
1,998,479 JPY ($24,372) compared with 990,178 JPY ($12,075) for
matched controls, resulting in a difference of 1,008,302 JPY
($12,296) (bootstrapped 95% CI 278,325.72 JPY–1,581,357.60 JPY
[$3,394–$19,285]). Costs for patients with DVT and PE were
significantly higher than for their matched controls when tested
with the gamma-distributed log-link generalized linear model
adjusted for age and gender (Po 0.0001 and P ¼ 0.0005, respec-
tively). Patients with both DVT and PE had an average 90-day cost
of 1,705,201 JPY ($20,795) associated with surgery compared with
2,098,639 JPY ($25,593) in patients with either DVT or PE only.
These resulted in a difference of –393,438 JPY (–$4,798) between
the two groups of patients (bootstrapped 95% CI –954,962.38 JPY
to 215,616.42 JPY [–$11,646 –to $2,629]).
The composition of costs incurred during the 90-day period
after surgery is presented in Figure. 2. For each category, costs
were greater in patients with VTE than in controls. The develop-
ment of a VTE requires additional resources to diagnose, treat,
and follow up the patient, resulting in the greater costs asso-
ciated with each category (Table 2). Differences between the two
groups for pharmacy, laboratory, medical, and room costs were
117,979 JPY ($1,439), 92,122 JPY ($1,123), 259,770 JPY ($3,168), and
413,061 JPY ($5,037), respectively. The greater difference in room
costs is driven by the difference in the length of the initial
hospital stay. There was a significantly longer hospitalization
related to MOS for patients who developed a VTE versus patients
without VTE (66.0 days vs. 42.0 days, P ¼ 0.0041).
The cumulative costs associated with MOS from 30 days prior
to the surgery date through 6 months after surgery are shown in
Figure. 3. Examining the monthly costs, there was an immediate
and large separation of costs between patients with VTE versus
matched controls. The greatest costs were incurred from the time
of surgery to 30 days after the procedure for both patients with
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Fig. 2 – Mean 90-day costs by category for patients with VTE
and matched control patients. VTE, venous
thromboembolism.
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between patients with VTE and controls increased to 363,893 JPY
($4,438) between 31 and 60 days after surgery, although the
absolute costs for both groups decreased. This is most likely
due to the added expenses of costly VTE treatment after surgery.
Costs incurred in patients with VTE remain on average much
higher than in patients without VTE throughout 5 months after
surgery. Mean costs were the same among all the patients 6
months after surgery, which may indicate that patients with VTE
no longer require treatment at this point. This result, however,
may also be indicative of the lack of sufficient patient data.Discussion
The development of a VTE in patients undergoing MOS results in
a 1.5-fold increase in the length of hospitalization and a 1.7-fold
increase in total costs over 90 days, resulting in a significant
burden to the health care system. The additional costs patients
incur are because of a VTE peak during the second month
following surgery, likely because of additional treatments and
testing following their VTE and perhaps because of the VTE
occurring closer to 30 days postsurgery.
The reported cumulative incidence of 0.774% is slightly lower
than what others have reported in the literature. Ollendorf et al.
[7] reported an in-hospital incidence of 1.1% and White et al. [14]
reported 0.9%. Oster et al. [12] reported a much higher incidence
of VTE following MOS (2.2%). Oster et al. [12] used only a claim
with a VTE diagnosis and the use of warfarin or UFH in defining
their VTE population, likely overstating the true number of VTEsTable 2 – Mean costs (JPY) by category for patients with
VTE
Cases Controls Ca
(n ¼ 26) (n ¼ 51) (n
Mean 1,992,713 1,128,560 1,9
Pharmacy costs 162,872 44,892 1
Laboratory costs 142,547 50,425 1
Medical costs 700,486 440,716 6
Room costs 1,076,337 663,276 1,0
Note. Controls matched on the basis of qualified subjects.
DVT, deep vein thrombosis; JPY, Japanese yen; PE, pulmonary embolismdue to the use of prophylactic therapy and need for an associated
diagnostic code to properly process the claim for reimbursement.
Data for the incidence rates of VTE following MOS in Japan are
widely varied. In patients undergoing hip surgery and receiving
thromboprophylaxis, the incidence rates of fatal PE, symptomatic
PE, and symptomatic DVTwere 0%, 0.03%, and 0.1%, respectively
[15]. In another study in which patients received a similar
thromboprophylaxis regimen, the incidence rates of fatal PE,
symptomatic PE, and proximal DVTwere all 0%, but the incidence
rate of asymptomatic DVTwas 6% [16]. Higher DVT incidence rates
of 22.6% and 43.6% were reported in Japanese patients undergoing
total hip and total knee arthroplasties, respectively, without antic-
oagulant prophylactic therapy [17]. The 8 (0.17%) cases of PE found
in the current study are supported by other researchers where PE
after MOS was found to be between 0.01% and 1.45% [17,18].
Furthermore, most studies report the occurrence of unsympto-
matic DVTwhile the present study evaluated symptomatic DVT.
Length of stay for the initial hospitalization was approxi-
mately six times what has been reported in the West. Oster et al.
[12] reported a total length of stay of 6.5 days for patients without
VTE and 11.1 days for patients with VTE, compared with 42.0 and
66.0 days, respectively, in our study. These findings are not
surprising given the typically longer length of stay in Japan.
There are several limitations that need to be considered within
this analysis. We used a very restrictive criteria for the identification
of a VTE; however, this ensures confidence that these were highly
probable true cases and therefore the cost differences seen are
likely reflective of the true cost differences. It should be noted that
some patients who discontinued anticoagulant treatment before 28
days postsurgery because of mild disease would have been
excluded because of this restrictive criteria, suggesting that the
resulting costs may have been higher due to more severe disease
among the identified cases. It is also possible that a few VTE cases
were classified as non-VTE cases because of our overly restrictive
criteria, but this would have driven the cost differences toward no
significant difference. The associated cumulative incidence is likely
underestimated because of these restrictive criteria.
Another limitation results from the reliance on hospital
electronic records in Japan. The current health care medical
records databases are still underdeveloped compared with the
West. Although these are developing rapidly, there remain lim-
itations in their current breadth. The current database captures
all electronic records for 13 hospitals from five prefectures.
Therefore, the number of surgeries was quite small. Indeed,
generalizability to the rest of Japan is somewhat problematic
because of the limited number of hospitals; however, the data-
base does include both Diagnosis Procedure Combination and
non–Diagnosis Procedure Combination hospitals, reflecting the
composition of care throughout Japan. Additional data frommore
rural hospitals and from the southern islands would be preferred.VTE, patients with DVT, and patients with PE.
DVT PE
ses Controls Cases Controls
¼ 24) (n ¼ 49) (n ¼ 8) (n ¼ 15)
10,365 1,159,582 1,998,479 990,178
56,426 45,943 144,718 37,925
39,065 50,861 179,061 62,016
97,128 447,562 626,376 424,436
12,402 679,161 1,115,445 497,313
; VTE, venous thromboembolism.
Fig. 3 – Cumulative mean costs (JPY) from 30 days prior to MOS through 6 months after surgery in patients with VTE and
matched control patients. MOS, major orthopaedic surgery; VTE, venous thromboembolism.
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represents a tremendous step forward in understanding the
economic burden of VTE on the health care system.
It is possible that patients who developed a VTE were at a
higher risk of developing a VTE because of comorbid conditions.
Unfortunately, we were not able to reliably develop a Charlson
Index for subjects because of the use of hospital-based claims.
We would be able to develop this comorbidity index only if each
subject used the same hospital for his or her primary care and
therefore, consistent recording of comorbid conditions could be
extracted. We were able to control for several factors though. By
matching on the hospital, surgery performed, and date of surgery
(within 6 months), we were able to control for changes in practice
patterns between hospitals and maintained the same balance
of surgery type in the cases and controls. In addition, we
controlled for age and gender in our multivariate analysis.
Therefore, we feel as though the impact of comorbid conditions
would only minimally impact our findings.
The results of this analysis highlight the significant increase
in costs associated with the development of a VTE following MOS.
In Japan, the use of pharmacologic VTE prophylaxis has been
reported at only 17% [19]. VTE is an easily preventable disease
with a substantial risk of morbidity and mortality in patients
following surgery. However, it has been reported that few physi-
cians in Asian countries use American College of Chest Physi-
cians recommended types of prophylaxis [20]. This may be due
to many factors, including physician awareness, risk of bleeding,
availability of guidelines, education, or reimbursement. With a
mortality rate of 32% in acute PE in Japanese subjects [21], the
avoidance of VTEs (DVT and PE) is important from a clinical
perspective. The avoidance of VTEs in Japanese patients through
more effective prophylactic treatment will help to reduce the
economic burden associated with MOS.
Source of financial support: This study was supported by
Sanofi-Aventis.
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